FDA Drug recall D-0821-2020
Dimercaptopropanesulfonate Sodium (DMPS), Aqueous injection solution, 50mg/mL 5 mL SDV, Rx only, McGuff Compounding Pharmacy Services, Inc
- FDA Drug
- Class II
- terminated
- Published 2020-02-05
On 2020-02-05 the FDA classified a Class II recall of Dimercaptopropanesulfonate Sodium (DMPS), Aqueous injection solution, 50mg/mL 5 mL SDV, Rx only, McGuff Compounding Pharmacy Services, Inc by Mcguff Compounding Pharmacy Services, citing presence of Particulate Matter: Particulates observed in vials release for dispensing.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0821-2020 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2019-02-14 |
| Published | 2020-02-05 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Mcguff Compounding Pharmacy Services |
| Distribution | AK, AZ, CA, CO, DC, FL, IN, MA, MT, NC, NJ, NY, OR, SC, TX, UT, VA, WA, WI |
Product
Dimercaptopropanesulfonate Sodium (DMPS), Aqueous injection solution, 50mg/mL 5 mL SDV, Rx only, McGuff Compounding Pharmacy Services, Inc. Santa Ana, CA 92704
Reason
Presence of Particulate Matter: Particulates observed in vials release for dispensing.
Identifiers
| code_info | Lot #18J1081, Exp 03/10/19 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0821-2020%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.